Some parts of the portal may cause error messages or display incorrectly due to the transition to a new provider of trading data

ABVX - Abivax S.A.


IEX Last Trade
7.625
0.155   2.033%

Share volume: 3,915
Last Updated: Thu 26 Dec 2024 08:30:20 PM CET
Research and Development in Biotechnology (except Nanobiotechnology): -0.11%

PREVIOUS CLOSE
CHG
CHG%

$7.47
0.16
2.07%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Fundamental analysis
4%
Profitability 0%
Dept financing 0%
Liquidity 0%
Performance 10%
Performance
5 Days
3.40%
1 Month
-10.59%
3 Months
-34.48%
6 Months
-41.36%
1 Year
-29.82%
2 Year
-8.43%
Key data
Stock price
$7.62
P/E Ratio 
0.00
DAY RANGE
$7.46 - $8.00
EPS 
$0.00
52 WEEK RANGE
$7.63 - $17.02
52 WEEK CHANGE
-$29.63
MARKET CAP 
804.250 M
YIELD 
N/A
SHARES OUTSTANDING 
63.277 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
N/A
BETA 
0.54
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$179,226
AVERAGE 30 VOLUME 
$133,542
Company detail
CEO: Marc de Garidel
Region: US
Website: www.abivax.com
Employees: 0
IPO year: -
Issue type: American Depository Receipt (ADR’s)
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services

We are a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases. We were incorporated as a société anonyme (limited liability company) on December 4, 2013 and registered at the Paris Trade and Company Register on December 27, 2013 for a period of 99 years until December 22, 2112, subject to extension or early dissolution, under the number 799 363 718. Our principal executive offices are located at 7-11 boulevard Haussmann 75009 Paris, France, and our telephone number is +33 (0) 1 53 83 08 41. We have one wholly owned subsidiary, Abivax LLC, a Delaware limited liability company, formed on March 20, 2023. Our agent for service of process in the United States is CT Corporation System, 1015 15th Street N.W., Suite 1000, Washington, D.C.

Recent news